MDAI Spectral AI Inc

$MDAI ... Expecting to hear good news soon about MDai being selected to develop the handheld device. Government funding for that may help with cash burn and may push any dilutive financing off. Hoping that they can find some more non-dilutive financing until they they get commercial revenue and ultimately positive cash flow.

$MDAI I am glad they clairifed the $2750 in patient fee which was on the one of the slides of the presentation. This is extra money and I bet it gets approved so this is great news and 2027 is looking good. Patience is the key because AI small cap stocks have been getting hammered all of 2026 and a big reversal is coming so get ready to ride the wave.

$MDAI not seeing this in the stock price just yet, but the market has cut supply here and it's only a matter of time now. I feel like I've said this before, so no idea how long.

$MDAI NT-APC 1523 is (Outpatient) Separate payment per scan ($2,750) willl likely be confirmed 1st Nov 2026 following 1st Sept announcement. NTAP (Inpatient) funding Nov 2027. Outpatient is the MOST important as it supports the ARDA rollout revenues through 2027. All these announcements are part of the strategic roll out. MORE GOOD NEWS TO COME 😜😜👍

$MDAI Amazing news. Approval for NTAP almost means guaranteed sales as far as I can see. Only thing is it takes a year to be approved so wonder what they'll be doing in the meantime?

$MDAI liquidity sweep didn't grab much, not many for sale down here. Seems tight and possibly ready to move up.

$MDAI risk appetite for tech coming back into the market. ROIC could be quite darn high here once revs flow.

$MDAI “Mama said there’d be days like this” to quote someone we all love. Low volume, weak back and forth. One of these days we’ll be all smiles with heavy upside trading. All we need is that first announced sale and prognosis on what’s to be expected in 2027/28. This family of medical products is well conceived, developed and field tested. Combined they will save untold dollars in medical expenses while providing patients with better early treatment. There is no better time to get in now while the price is cheap!

$MDAI just upped one of my portfolios from 8500 to 10000 shares over yesterday and today

$MDAI added a few more. I have so many shares relative to my portfolio I am going to puke.

$MDAI ... Awfully quiet on the home front. Sure would be nice to hear something about the commercialization effort.

$MDAI other than a brief run to $3 on FDA news, this has been around a base around 1.6 for the last 10 (!!) months. For a 50M market cap company this is absurd, but given how slow management has performed, could be another 10 months between 1.5 and 2

$MDAI With elections just ahead there will likely be some market impact. Any ideas regarding Spectral AI? Up, down or nothing? No volume today. We need some positive news.

$MDAI Summary Counterargument What looks like "nothing new" is actually the necessary, unglamorous groundwork of medical commercialization: submitting reimbursement applications (NTAP), expanding the clinical label to satisfy hospital purchasing boards, and pitching to medical assemblies (like the recent ACEP conference) to build a sales pipeline. The real test of revenue generation will begin in Q4 2026 and head into 2027. Spectral AI is estimated to report its Q3 2026 earnings on Tuesday, November 10, 2026.

3. The Investor Inducement / Funding Environment Micro-cap medical technology companies face an incredibly tough financing market. If their recent attempts to induce investors underperformed, it may reflect broader market headwinds for pre-revenue medical AI rather than a failure specific to Spectral AI's tech. • With $14.0 million in cash reported in their mid-2026 financials, they maintain a decent runway to bridge the gap into late 2026 commercialization. • Because 90%+ of their historical R&D funding has come from non-dilutive government grants (BARDA), they haven't had to dilute shareholders as aggressively as their peers just to keep the lights on.$MDAI

$MDAI 1. Why They Are Expanding Labeling Now While additional clinical studies do mean added expenses, expanding the labeling to include burns of the head, hands, and feet is a critical move to maximize their Total Addressable Market (TAM). • The Commercial Reality: Hospitals are highly resistant to buying expensive diagnostic equipment if it can only be used on a limited subset of patients. • Value Proposition: By validating the DeepView System for complex anatomical areas (head, hands, feet), Spectral AI removes a major roadblock to institutional adoption, making the platform a "must-have" rather than a niche tool. Google AI

$MDAI ... This stock really needs a jump start. Seems like a great product but a crappy investment so far. I really thought the price would go up with the FDA approval.

$MDAI good news here today with basically no volume/ market reaction. However some needed pieces starting to fall into place and news starting to roll faster. Also of note, Fidelity now covering social sentiment score for the stock. Flipped a batch today and rebought more on the drop.

$MDAI I’m hoping it holds the lower trend line of this wedge. We’ll see….but I’m still here and still holding.

$MDAI The election will cause some overall market fluctuations for sure, but that is always to be expected. As for Spectral AI… we sit and wait until the sales start rolling in. Just a matter of time… and it won’t be long now. If their “end-of-year” guidance is accurate… any day now!🚀